Evelo Biosciences Inc. (EVLO) Prices 4.5M Share Common Offering at $15/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- Kroger cuts same-store sales outlook, keeps earnings guidance
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
After-Hours Stock Movers 01/28: (KOSS) (GME) (NVAX) Higher; (EVLO) (ADMP) (JNP) Lower (more...)
January 28, 2021 6:00 PM ESTToday's After-Hours Stock Movers:
Koss Corporation (NASDAQ: KOSS) 47.9% HIGHER; Robinhood will again allow limited trades
GameStop Corp. (NYSE: GME) 35% HIGHER; Robinhood will again allow limited trades
Novavax, Inc. (Nasdaq: NVAX) 29% HIGHER; announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical... More
Evelo Biosciences Inc. (EVLO) Announces $50M Proposed Public Offering of Common Stock
January 28, 2021 4:33 PM ESTEvelo Biosciences, Inc. (Nasdaq: EVLO) (Evelo), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. Evelo expects to grant the underwriters a 30-day option, solely to cover over-allotments, if any, to purchase up to an... More
